Loading
Biomarkers / Alzheimer Disease / Neuroimaging · Journal article
Magnetic Resonance Imaging · August 3, 2026
Reinforces what was already believed, rather than introducing something new.
This umbrella review synthesizes evidence from 15 systematic reviews (mostly low methodological quality) on quantitative susceptibility mapping as a biomarker for iron accumulation in neurodegenerative diseases. QSM demonstrates diagnostic promise with superior or comparable sensitivity to conventional MRI techniques, and shows disease-specific iron distribution patterns that correlate with clinical severity; however, substantial heterogeneity and methodological limitations necessitate cautious interpretation.
Umbrella review of systematic reviews and meta-analyses. Studies evaluating QSM in patients with neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, atypical Parkinsonism).. Intervention: Quantitative susceptibility mapping (QSM), an advanced MRI technique for in vivo measurement of tissue magnetic susceptibility as a proxy for iron content. Compared with: Conventional R2* and susceptibility-weighted imaging (SWI) techniques.
QSM provides comparable or higher diagnostic sensitivity and reliability than conventional R2* and SWI techniques, particularly for deep gray matter structures Iron overload in substantia nigra pars compacta is a robust biomarker for Parkinson's disease that correlates with motor severity and disease duration Elevated χ in putamen and globus pallidus effectively distinguishes multiple system atrophy and progressive supranuclear palsy from idiopathic PD
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize QSM as a promising non-invasive neuroimaging biomarker for quantifying iron in neurodegenerative diseases and supporting differential diagnosis of parkinsonian syndromes. However, the low methodological quality of underlying reviews and high heterogeneity warrant cautious implementation pending higher-quality evidence.
An umbrella review of 15 systematic reviews and meta-analyses confirming QSM as a sensitive biomarker for iron quantification across neurodegenerative diseases, but methodological quality is low and findings require cautious interpretation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize QSM as a promising non-invasive neuroimaging biomarker for quantifying iron in neurodegenerative diseases and supporting differential diagnosis of parkinsonian syndromes. However, the low methodological quality of underlying reviews and high heterogeneity warrant cautious implementation pending higher-quality evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Pathological iron accumulation is a common pathophysiological hallmark across multiple neurodegenerative diseases (NDDs), motivating the need for accurate, non-invasive quantification methods. Quantitative susceptibility mapping (QSM) is an advanced magnetic resonance imaging (MRI) technique that enables in vivo measurement of tissue magnetic susceptibility (χ), providing a sensitive proxy for iron content. This umbrella review systematically evaluates the diagnostic accuracy, clinical correlations, and distinct iron distribution patterns of QSM in major NDDs, such as Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and atypical Parkinsonism. We included 15 (13/15 were rated Low or Critically Low on AMSTAR 2) systematic reviews and meta-analyses (through July 15, 2026); however, the findings should be interpreted cautiously because of heterogeneity and the low methodological quality. A Corrected Covered Area (CCA) analysis demonstrated only slight overlap of primary studies across the included reviews (CCA = 5.42%). Collectively, the evidence indicates that QSM provides comparable or higher diagnostic sensitivity and reliability than conventional R2* and SWI techniques, particularly for deep gray matter structures. The findings support significant iron overload in the substantia nigra, particularly in the pars compacta, as a robust biomarker for PD that correlates with motor severity and disease duration. Furthermore, regional iron profiling in the basal ganglia is critical for differential diagnosis; specifically, elevated χ in the putamen and globus pallidus effectively distinguishes multiple system atrophy and progressive supranuclear palsy from idiopathic PD. Distinctively, AD and ALS exhibit specific χ alterations in the thalamus, motor cortex, and hippocampus, reflecting divergent iron-related pathophysiological mechanisms, which correlate with cognitive impairment and upper motor neuron signs. Overall, QSM shows diagnostic promise and offers mechanistic insights into iron-related neurodegenerative processes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.